MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Bladder and Urothelial Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,070 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,070 works in the cohort · of 4,299,418page 11 of 62

Labels cover 8 of 3,070 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,070 of 3,070 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Updates to Microhematuria: AUA/SUFU Guideline (2025)
Daniel A. Barocas, Yair Lotan, Richard S. Matulewicz, Jay D. Raman, Mary E. Westerman, Erin Kirkby +2 more
2025· article· es· The Journal of Urology· Medicine
machine prediction:candidate · noneconsensus · none
42
citations
affunlabeled
Enfortumab Vedotin in urothelial cancer
Marie Alt, Carlos Stecca, Swanee Tobin, Di Jiang, Srikala S. Sridhar
2020· review· en· Therapeutic Advances in Urology· Medicine
machine prediction:candidate · noneconsensus · none
41
citations
affunlabeled
Clear Cell Urothelial Carcinoma
Justin Bateman, Bojana Djordjevic, Trevor A. Flood, Eric C. Bélanger
2016· review· en· International Journal of Surgical Pathology· Medicine
machine prediction:candidate · noneconsensus · none
39
citations
affno abstractunlabeled
LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Jonathan E. Rosenberg, M. Milowsky, Chethan Ramamurthy, Nataliya Mar, Rana R. McKay, Terence W. Friedlander +14 more
2022· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
38
citations
affaboutunlabeled
Does patient age affect survival after radical cystectomy?
David Horovitz, Polat Türker, Peter J. Boström, Tuomas Mirtti, Martti Nurmi, Cynthia Kuk +5 more
2012· article· en· British Journal of Urology· Medicine
machine prediction:candidate · noneconsensus · none
38
citations

How this was built: Screen · Findings · About